Exocrine Pancreatic Insufficiency Market Analysis and Value Forecast Snapshot by End-use Industry 2017-2023

Exocrine Pancreatic Insufficiency Market report provides the latest market data along with industry future trends, which keeps tracking of users driving revenue growth rate of Exocrine Pancreatic Insufficiency Market by disease management(nutritional management, pancreatic enzyme replacement therapy, life style modifications approach), by therapeutics drugs(creon, zenpep, pancreaze, ultresa, viokace, pertzye) market status and outlook of global and major regions, from manufacturers, and end industries. As this report is expected to help key players among the Exocrine Pancreatic Insufficiency Market it includes the five years Industry analysis and the 6 years annual forecast from 2017 to 2023. Some of the prominent participants in the Global Exocrine Pancreatic Insufficiency Market are Abbie, Inc., Allergan plc, Digestive Carew, Inc., Cilian AG, Anthera Pharmaceuticals, Inc. and AzuRx Biopharma, Inc. MSD. Furthermore, the global exocrine pancreatic market is anticipated to grow at a CAGR between 8.0% – 8.6% over the period of 2017 to 2023.

The Increasing Global Incidences for Exocrine Pancreatic Insufficiency is one of the Prime Reasons Increasing Demand of Advanced Therapeutics Globally

Exocrine pancreatic insufficiency (EPI) is a serious digestive problem and caused by improper digestion, and exocrine pancreatic insufficiency. It is a kind of a chronic disease caused by deficiency in pancreatic enzyme. Global revenue of exocrine pancreatic insufficiency market, was valued at more than USD 700 million in 2015, and is projected to surpass USD X.X Billion by 2023. Furthermore, the global exocrine pancreatic market is anticipated to grow at a CAGR between 8.0% – 8.6% over the period of 2017 to 2023. Increasing global incidences for exocrine pancreatic insufficiency is one of the prime reasons increasing demand of advanced therapeutics globally. Furthermore, presence of significant number of pipeline drugs and lipase treatment in diabetic patients, optimizes the chymotrypsin and trypsin level are expected to drive the global market for exocrine pancreatic insufficiency market over the forecast period. Moreover, the EPI market has been segmented by the mode of disease management, therapeutics drugs, diagnostic tests and geography. Mode of disease management contains nutrition management, PERT. Therapeutics drugs consist Creon, Zenpep, Pancreaze, Ultresa and Pertzye.

North America Dominated the Global Market of Exocrine Pancreatic Insufficiency by Accounting for the Largest Market Share

The report covers the analysis of exocrine pancreatic insufficiency market by therapeutics and diagnostic tests. Furthermore, the report covers the analysis of global as well as regional markets of exocrine pancreatic insufficiency. North America dominated the global market of exocrine pancreatic insufficiency by accounting for the largest market share. While the Asia Pacific region is expected to grow at a highest CAGR over the forecast period 2017 – 2023. Moreover, the report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand globally as well as regionally. Moreover, Infinium Global Research- Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider.

Major Key Players Mentioned in this Report:

The report on EPI market covers the companies such as Abbie, Inc., Allergan plc, Digestive Carew, Inc., Cilian AG, Anthera Pharmaceuticals, Inc. and AzuRxBiopharma, Inc. MSD.

Table of Contents:-

1. Preface

1.1. Report description

1.2. Market overview

1.3. Market segmentations

1.4. Competition

1.5. conclusion

2. Executive summary

3. Exocrine Pancreatic Insufficiency Industry Analysis


3.2.market dynamics




3.3.competitive analysis

3.4.Porter’s five forces model

3.5.IGR- Growth matrix analysis

3.6. Regulatory Framework analysis by region

3.6.1North America


3.6.3RoW (Including APAC, and LATAM)

4. Exocrine Pancreatic Insufficiency Regulatory Aspects

4.1. North America

4.2. Europe

4.3. Asia Pacific

4.4. Rest of the world

5. Exocrine Pancreatic Insufficiency Market by Disease Management

5.1. Nutritional Management

5.2. Pancreatic Enzyme Replacement Therapy (PERT)

5.3. Life Style Modifications Approach

6. Exocrine Pancreatic Insufficiency Market By Therapeutics Drugs

6.1. Creon

6.2. Zenpep

6.3. Pancreaze

6.4. Ultresa

6.5. Viokace

6.6. Pertzye

7. Exocrine Pancreatic Insufficiency Market By Diagnosis

7.1. Magnetic resonance imaging (MRI)

7.2. CT scanning

7.3. Endoscopic ultra-sonography (EUS)

7.4. Blood tests

7.5. Other tests

8. Exocrine Pancreatic Insufficiency Market By Geography

8.1. North America

8.2. Asia Pacific

8.3. Europe

8.4. South America

8.5. Rest of the world.

9. Company profile

9.1. Abbvie Inc.

9.2. Allergan plc.

9.3. Nordmark Arzneimittel GmbH & Co. KG

9.4. Digestive Care, Inc.

9.5. Cilian AG

9.6. Anthera Pharmaceuticals Inc.

9.7. Janssen Pharmaceuticals Inc.

9.8. AzurRxBioPharma Inc.

Browse Detailed TOC, Description, and Companies Mentioned in Report @


Reset Password